Afadel 40mg Tablet

\

Undesired symptoms or responses vary from person to person as the human body reacts differently to the Afadel 40mg Tablet, but they typically resolve naturally within a few days as the body adjusts to the medicine, requiring no medical attention. In case these symptoms don't go away and you face severe side effects, then immediately consult your doctor or medical team. Some of the common side effects of the Afadel 40mg Tablet are:
Fatigue
Headache, Increased glucose level in blood Fever Imsomnia (diffficulty in sleeping) High blood pressure
Rash
Indigestion
Nausea diarrhea or constipation
Tremors
Loss of appetite
Low blood count
kidney damage

Afadel 40mg Tablet should not be chewed, opened, or crushed; it must be swallowed to increase the effectiveness of the drug. It is an oral medication that is taken once a day, at the same time each day, before food. One should wait for at least 3 hours before taking Afadel 40mg Tablet.

Afadel 40mg Tablet helps the cancer cells stop their growth. It inhibits the ErbB family of proteins, which includes EGFR (also known as the epidermal growth factor receptor, or ErbB1, ErbB2, ErbB3, and ErbB4) and HER2. Growth and proliferation of cancer cells can be stopped or slowed the growth of cancer. Changes in the proteins can alter the cell division and multiplication of cancer cells.

Barron, F., de la Torre-Vallejo, M., Luna-Palencia, R. L., Cardona, A. F., & Arrieta, O. (2025). The safety of afatinib for the treatment of non-small cell lung cancer. Expert Opinion on Drug Safety, 15(11), 1563-1572.
Batra, U., Sharma, M., Jain, P., Narayan, S., Jain, A., Soni, S., & Nathany, S. (2024). Indian experience of Afatinib for EGFR mutation-positive advanced lung adenocarcinoma: a real-world retrospective study. Indian Journal of Cancer, 61(4), 671-675.
Igawa, S., Ono, T., Kasajima, M., Kusuhara, S., Otani, S., Fukui, T.,& Naoki, K. (2020). Real-world assessment of afatinib for patients with EGFR-positive non-small cell lung cancer. Investigational New Drugs, 38(6), 1906-1914.
Wu, Y. L., Zhou, C., Hu, C. P., Feng, J., Lu, S., Huang, Y., & Geater, S. L. (2024). Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. The lancet oncology, 15(2), 213-222.
Zhang, L., Luo, Y., Chen, J., Cheng, T., Yang, H., Pan, C., & Jiang, Z. (2021). Efficacy and Safety of Afatinib in the Treatment of Advanced Non‐Small‐Cell Lung Cancer with EGFR Mutations: A Meta‐Analysis of Real‐World Evidence. Journal of Oncology, 2021(1), 8736288.